首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

2102955

全球卒中臨床試驗趨勢：發展現況與分析（2026 年）

Global Stroke Clinical Trials Landscape: Developments and Analysis, 2026 Update

出版日期: 2026年07月21日 | 出版商:

Knowledge Sourcing Intelligence | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

臨床研發日益著重於加速功能恢復、降低致殘率、最佳化再灌注策略、預防腦血管事件復發。影像技術、再生醫學、人工智慧和精準醫學的進步不斷推動著中風臨床試驗的格局演變。

中風仍然是全球主要的死亡和長期殘疾原因之一。缺血性中風尤其佔了臨床研發活動的大部分。目前的研究重點包括溶栓治療、機械取栓、神經保護、幹細胞治療、以及二級預防策略的最佳化。臨床試驗分析能夠為在臨床實驗、研發管線成熟度、試驗階段、申辦者活動、監管趨勢、病患入組趨勢以及商業化機會等方面提供寶貴的見解。

市場促進因素

全球中風負擔日益加重。

與老化、高血壓、糖尿病、肥胖、心房顫動和其他心血管危險因子相關的中風發生率不斷上升，持續推動創新療法的需求。中風帶來的巨大臨床和經濟負擔也促使人們加強對神經系統藥物研發的投入。

神經保護療法研發的擴展

神經保護劑研究的拓展旨在保護腦組織並改善急性缺血性腦中風患者的長期神經功能恢復。多種在臨床實驗藥物正處於中期和後期臨床開發階段。

再灌注策略的進展

在正在進行的臨床試驗中，我們不斷最佳化溶栓藥物、機械取栓術和影像引導介入策略，旨在改善治療效果並擴大急性中風治療的範圍。

擴大數位化臨床試驗的應用

人工智慧、數位健康平台、穿戴式監測設備、遠端醫療和分散式臨床試驗模式正在改善患者招募、監測和數據收集，同時也提高了營運效率。

本報告調查了中風臨床試驗的全球趨勢，概述了中風藥物開發平臺，按適應症、給藥途徑、分子類型和地區對管線資產進行了分類，按階段分類了臨床試驗活動的分佈情況，對臨床試驗設計進行了比較分析，分析了成功機率和風險，並介紹了主要研發公司的努力和未來前景。

作用機轉概述
- 抗血栓治療
- 溶栓藥物
- 神經保護藥物
- 抗發炎作用
- 血管修復機制
- 神經再生機制
- 利用幹細胞的作用機制
- 新型作用機制
作用機制的分類與分析
- 已確立的作用機制
- 新型作用機制
- First-in-Class候選人
- 同類最佳候選人
模式情況
- 小分子藥物
- 生物製藥
- 細胞療法
- 基因治療
- RNA療法
- 聯合治療
創新指標評估
基於作用機制的競爭性基準分析

第5章臨床開發智慧

臨床試驗環境：概述
臨床試驗活動：按階段
- 臨床前項目
- 第一階段計劃
- 第二階段計劃
- 第三階段計劃
- 申請已提交，目前正在接受監管審查。
臨床試驗設計基準測試
- 樣本大小分析
- 主要結果指標分析
- 次要結局指標分析
- 一段時間內的基準測試
- 患者選擇標準
受試者招募分析
臨床試驗成功與失敗分析
監管發展趨勢
即將到來的重大臨床里程碑

第6章：全球卒中臨床試驗環境分析：依細分市場分類

臨床試驗階段
- 臨床前和 I 期試驗
- 第二階段
- 第三階段
- 申請已提交/審核中
按類型描邊
- 缺血性中風
- 出血性中風
- 短暫性腦缺血發作（TIA）
- 其他
依藥物類型
- 溶栓藥物
- 抗血小板藥物
- 抗凝血劑
- 其他
透過行政途徑
- 口服
- 靜脈注射
- 其他

第7章：成功機率與風險分析

藥物研發風險框架
相變機率分析
- 從臨床前試驗到 I 期臨床試驗
- 第一階段至第二階段
- 第二階段至第三階段
- 已獲準進入第三期臨床試驗
風險調整後的管道評估
輟學率分析
臨床危險因子
監理風險評估
商業化風險評估
成功機率加權銷售預測
情境建模

第8章市場上市時機/商業性可能性

核准時間預測分析
產品發布計劃
市場啟動順序評估
市場進入時機分析
銷售高峰期的潛在評估
主要開發產品的銷售預測
與競品上市時間重疊分析
市場滲透率展望
長期市場趨勢

第9章：管線產業的競爭格局

競爭環境概述
公司特定管道競爭力評估
按管道規模分類的主要贊助商
臨床開發階段的主要贊助商
創新領導力分析
管道濃度評估
公司定位：領導企業vs. 挑戰者公司
競爭標竿矩陣
新參與企業分析
策略定位評估

第10章區域分析

北美洲
歐洲
亞太地區
拉丁美洲

第11章主要國家分析

加拿大
德國
中國
日本
印度

第12章：交易與投資展望

授權協議
聯合開發合作
研究夥伴關係
M&A
創業投資
私募股權投資
公共資金舉措
策略聯盟的發展趨勢
投資熱點
未來資金籌措前景

第13章：未來展望與策略洞察

Genentech
Boehringer Ingelheim
F. Hoffmann-La Roche Ltd
Novartis AG
Bayer AG
Johnson & Johnson
Daiichi Sankyo
Sanofi
Novo Nordisk
AstraZeneca PLC
Merck & Co., Inc.
GlaxoSmithKline plc
Eli Lilly and Company
AbbVie Inc.
Pipelin
- 管道定位
- 戰略重點
- 未來展望
未來管道開發方案
新興技術評估
策略建議
2035年取得成功的關鍵要素

第14章：調查方法與資料框架

簡介目錄

Product Code: KSI-008953

Clinical development is increasingly focused on improving functional recovery, reducing disability, enhancing reperfusion strategies, and preventing recurrent cerebrovascular events. Advances in imaging technologies, regenerative medicine, artificial intelligence, and precision medicine continue to reshape the stroke clinical trial landscape.

Stroke remains one of the leading causes of mortality and long-term disability worldwide, with ischemic stroke accounting for the majority of clinical development activity. Current research is centered on optimizing thrombolytic therapy, mechanical thrombectomy, neuroprotection, stem cell therapy, and secondary prevention strategies. Clinical trials analysis provides valuable insights into investigational therapies, pipeline maturity, trial phases, sponsor activities, regulatory developments, enrollment trends, and commercialization opportunities.

Market Drivers

Rising Global Burden of Stroke

The increasing incidence of stroke associated with aging populations, hypertension, diabetes, obesity, atrial fibrillation, and other cardiovascular risk factors continues to drive demand for innovative therapeutic approaches. The substantial clinical and economic burden of stroke is encouraging greater investment in neurological drug development.

Expansion of Neuroprotective Therapy Development

Growing research into neuroprotective agents aims to preserve brain tissue during acute ischemic stroke and improve long-term neurological recovery. Several investigational therapies are progressing through mid- and late-stage clinical development.

Advances in Reperfusion Strategies

Ongoing clinical trials continue to optimize thrombolytic agents, mechanical thrombectomy techniques, and imaging-guided intervention strategies to improve treatment outcomes and expand eligibility for acute stroke therapies.

Increasing Adoption of Digital Clinical Trials

Artificial intelligence, digital health platforms, wearable monitoring devices, telemedicine, and decentralized clinical trial models are improving patient recruitment, monitoring, and data collection while increasing operational efficiency.

Market Restraints

Complex Clinical Trial Design

Stroke clinical trials require large patient populations, rapid enrollment, standardized imaging protocols, and long-term functional outcome assessments, making development expensive and operationally complex.

Stringent Regulatory Requirements

Regulatory agencies require strong evidence demonstrating meaningful improvements in neurological recovery, functional independence, and long-term safety before approving new stroke therapies.

Patient Recruitment Challenges

The narrow therapeutic window for acute stroke treatment and strict patient eligibility criteria continue to create enrollment challenges for many clinical studies.

Clinical Trial and Technology Insights

The global stroke clinical trials market can be segmented by clinical trial phase, stroke type, therapy type, mechanism of action, sponsor type, route of administration, and geography.

By clinical trial phase, the market includes Phase I, Phase II, Phase III, and Phase IV trials. Phase II and Phase III studies account for the largest share of ongoing development activity as sponsors evaluate efficacy, safety, and functional outcomes in larger patient populations.

By stroke type, the market comprises ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke dominates clinical development because it represents the majority of stroke cases and offers numerous opportunities for therapeutic innovation.

By therapy type, investigational programs include thrombolytic therapies, neuroprotective therapies, regenerative medicine, stem cell therapies, anticoagulants, antiplatelet therapies, anti-inflammatory therapies, and combination treatments. Neuroprotective and regenerative therapies are emerging as important areas of research because they aim to improve neurological recovery beyond reperfusion alone.

By mechanism of action, pipeline therapies target thrombus dissolution, neuronal protection, vascular repair, inflammation modulation, neuroregeneration, and secondary stroke prevention.

By sponsor type, the market includes pharmaceutical companies, biotechnology firms, academic institutions, government organizations, and contract research organizations (CROs). Collaborative partnerships between academia and industry continue to accelerate clinical development.

By route of administration, investigational therapies include intravenous, oral, intra-arterial, injectable, and device-assisted interventions. Intravenous therapies remain central to acute stroke management, while oral therapies dominate secondary prevention.

Technological advances including artificial intelligence-assisted imaging, advanced neuroimaging biomarkers, digital health platforms, decentralized clinical trials, wearable monitoring systems, and electronic patient-reported outcomes are improving trial efficiency and supporting precision medicine approaches.

Clinical Trial Trends

The stroke clinical trial landscape continues to evolve toward personalized and technology-enabled neurological care.

Key trends include:

Expansion of Phase II and Phase III clinical development.
Increasing investment in neuroprotective therapies.
Growing use of regenerative medicine and stem cell therapies.
Broader adoption of artificial intelligence in clinical trial design.
Expansion of decentralized and digital clinical trials.
Increasing use of imaging biomarkers for patient selection.
Greater emphasis on functional recovery and long-term neurological outcomes.

Regional Insights

North America remains the leading region for stroke clinical trials because of advanced stroke care infrastructure, extensive research funding, well-established regulatory pathways, and strong participation from pharmaceutical and biotechnology companies. Comprehensive stroke centers and academic institutions continue to support large multicenter studies.

Europe maintains a significant position through multinational clinical collaborations, strong academic research networks, and established stroke registries. Regulatory harmonization and large patient populations support continued clinical development.

Asia-Pacific is expected to experience the fastest growth owing to rising stroke incidence, expanding healthcare infrastructure, increasing research investment, and growing participation in multinational clinical trials across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are increasingly participating in multinational stroke studies as healthcare infrastructure and clinical research capabilities continue to improve.

Competitive Landscape

The stroke clinical trials landscape includes multinational pharmaceutical companies, biotechnology firms, academic medical centers, government research organizations, and contract research organizations.

Organizations continue investing in neuroprotective therapies, regenerative medicine, artificial intelligence, advanced imaging technologies, precision medicine, and digital clinical trial platforms. Strategic collaborations, licensing agreements, mergers and acquisitions, and global multicenter trials remain important strategies for accelerating clinical development and strengthening competitive positioning.

Future Outlook

The future of stroke clinical trials will be driven by advances in precision neurology, regenerative medicine, artificial intelligence, digital health, and personalized therapeutics. Continued research into neuroprotection, stem cell therapies, novel thrombolytics, and imaging-guided treatment is expected to improve functional recovery while expanding future commercialization opportunities.

Greater integration of decentralized trial models, real-world evidence, wearable technologies, and biomarker-guided patient selection is expected to enhance trial efficiency and accelerate regulatory approvals through 2035.

Conclusion

The global Stroke Clinical Trials Analysis market is expected to experience sustained growth through 2035, supported by increasing investment in neurological research, advances in neuroprotective therapies, expanding use of precision medicine, and continuous innovation in acute stroke management. Although challenges related to trial complexity, patient recruitment, and regulatory requirements remain, ongoing advances in artificial intelligence, regenerative medicine, and digital clinical research are expected to transform stroke drug development and improve patient outcomes.

Key Benefits of this Report

Comprehensive analysis of the global stroke clinical trials landscape.
Detailed evaluation of investigational therapies, clinical trial phases, and pipeline maturity.
Competitive assessment of sponsor activities, strategic collaborations, and development trends.
Insights into regulatory developments, emerging technologies, and commercialization opportunities.
Valuable resource for pharmaceutical companies, biotechnology firms, contract research organizations, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Clinical development planning, pipeline benchmarking, competitive intelligence, licensing and partnership evaluation, investment analysis, regulatory strategy, portfolio optimization, commercialization planning, and strategic decision-making.

Report Coverage

Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
Comprehensive analysis of the global stroke clinical trials landscape by clinical trial phase, stroke type, therapy type, mechanism of action, sponsor type, route of administration, and geography
Evaluation of investigational therapies, clinical development progress, pipeline maturity, enrollment trends, sponsor activities, and emerging technologies
Assessment of regulatory developments, strategic collaborations, licensing agreements, mergers and acquisitions, and commercialization strategies
Analysis of neuroprotective therapies, thrombolytics, regenerative medicine, stem cell therapies, artificial intelligence, digital clinical trials, and future development opportunities through 2035.

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Stroke Clinical Development Landscape Overview
1.3 Key Pipeline Intelligence Highlights
1.4 Clinical Innovation Trends
1.5 Mechanism of Action Evolution
1.6 Risk-Adjusted Pipeline Assessment
1.7 Competitive Positioning Snapshot
1.8 Expected Regulatory and Commercial Milestones
1.9 Strategic Conclusions

2. Pipeline Overview

2.1 Stroke Therapeutics Pipeline Overview
- 2.1.1 Pipeline Asset Distribution by Development Phase
- 2.1.2 Historical Pipeline Growth Trends
- 2.1.3 Active versus Inactive Programs
- 2.1.4 Emerging Clinical Development Trends
2.2 Pipeline Assets by Sponsor Type
- 2.2.1 Large Pharmaceutical Companies
- 2.2.2 Biotechnology Companies
- 2.2.3 Academic and Research Organizations
2.3 Pipeline Assets by Indication
- 2.3.1 Acute Ischemic Stroke
- 2.3.2 Hemorrhagic Stroke
- 2.3.3 Secondary Stroke Prevention
- 2.3.4 Post-Stroke Recovery and Rehabilitation
- 2.3.5 Neuroprotection in Stroke
2.4 Pipeline Assets by Route of Administration
2.5 Pipeline Assets by Molecule Type
2.6 Pipeline Assets by Geographic Origin
2.7 Pipeline Maturity Assessment
2.8 Pipeline Productivity Analysis

3. Disease & Unmet Need Analysis

3.1 Disease Overview
- 3.1.1 Stroke Classification
- 3.1.2 Disease Burden Assessment
- 3.1.3 Epidemiological Overview
3.2 Current Treatment Landscape
- 3.2.1 Standard of Care Analysis
- 3.2.2 Approved Pharmacological Interventions
- 3.2.3 Mechanical and Procedural Interventions
3.3 Unmet Clinical Needs
- 3.3.1 Acute Intervention Gaps
- 3.3.2 Neuroprotection Challenges
- 3.3.3 Long-Term Recovery Limitations
- 3.3.4 Recurrence Prevention Challenges
3.4 Future Therapeutic Opportunities
3.5 Innovation White Space Analysis

4. Mechanism & Modality Landscape

4.1 Mechanism of Action Landscape
- 4.1.1 Antithrombotic Therapies
- 4.1.2 Thrombolytic Agents
- 4.1.3 Neuroprotective Agents
- 4.1.4 Anti-Inflammatory Mechanisms
- 4.1.5 Vascular Repair Mechanisms
- 4.1.6 Neuroregenerative Mechanisms
- 4.1.7 Stem Cell-Based Mechanisms
- 4.1.8 Emerging Novel Mechanisms
4.2 Mechanism Clustering Analysis
- 4.2.1 Established Mechanisms
- 4.2.2 Novel Mechanisms
- 4.2.3 First-in-Class Candidates
- 4.2.4 Best-in-Class Candidates
4.3 Modality Landscape
- 4.3.1 Small Molecules
- 4.3.2 Biologics
- 4.3.3 Cell Therapies
- 4.3.4 Gene Therapies
- 4.3.5 RNA-Based Therapies
- 4.3.6 Combination Therapies
4.4 Innovation Index Assessment
4.5 Mechanism-Based Competitive Benchmarking

5. Clinical Development Intelligence

5.1 Clinical Trial Landscape Overview
5.2 Clinical Trial Activity by Phase
- 5.2.1 Preclinical Programs
- 5.2.2 Phase I Programs
- 5.2.3 Phase II Programs
- 5.2.4 Phase III Programs
- 5.2.5 Filed and Under Regulatory Review Programs
5.3 Trial Design Benchmarking
- 5.3.1 Sample Size Analysis
- 5.3.2 Primary Endpoint Analysis
- 5.3.3 Secondary Endpoint Analysis
- 5.3.4 Duration Benchmarking
- 5.3.5 Patient Selection Criteria
5.4 Recruitment Intelligence
- 5.4.1 Enrollment Trends
- 5.4.2 Recruitment Timelines
- 5.4.3 Geographic Recruitment Distribution
5.5 Clinical Success and Failure Analysis
- 5.5.1 Historical Success Rates
- 5.5.2 Failure Drivers
- 5.5.3 Trial Termination Trends
- 5.5.4 Clinical Attrition Patterns
5.6 Regulatory Development Intelligence
- 5.6.1 Fast Track Designations
- 5.6.2 Breakthrough Therapy Designations
- 5.6.3 Orphan and Special Regulatory Programs
5.7 Key Upcoming Clinical Milestones

6. Global Stroke Clinical Trials Landscape Report Segmentation Analysis

6.1 By Clinical Trial Phase
- 6.1.1 Preclinical & Phase I
- 6.1.3 Phase II
- 6.1.4 Phase III
- 6.1.5 Filed & Under Review
6.2 By Stroke Type
- 6.2.1 Ischemic Stroke
  - 6.2.1.1 Thrombotic
  - 6.2.1.2 Embolic
- 6.2.2 Hemorrhagic Stroke
- 6.2.3 Transient Ischemic Attack
- 6.2.4 Others
6.3 By Drug Type
- 6.3.1 Thrombolytics
- 6.3.2 Antiplatelets
- 6.3.3 Anticoagulants
- 6.3.4 Others
6.4 By Route of Administration
- 6.4.1 Oral
- 6.4.2 Intravenous
- 6.4.3 Others

7. Probability of Success & Risk Analysis

7.1 Drug Development Risk Framework
7.2 Phase Transition Probability Analysis
- 7.2.1 Preclinical to Phase I
- 7.2.2 Phase I to Phase II
- 7.2.3 Phase II to Phase III
- 7.2.4 Phase III to Approval
7.3 Risk-Adjusted Pipeline Assessment
7.4 Attrition Rate Analysis
7.5 Clinical Risk Factors
7.6 Regulatory Risk Assessment
7.7 Commercial Risk Assessment
7.8 Probability-Weighted Revenue Forecasting
7.9 Scenario Modeling
- 7.9.1 Base Case
- 7.9.2 Optimistic Case
- 7.9.3 Conservative Case

8. Launch Timeline & Commercial Potential

8.1 Expected Approval Timeline Analysis
8.2 Anticipated Product Launch Calendar
8.3 Launch Sequencing Assessment
8.4 Market Entry Timing Analysis
8.5 Peak Sales Potential Assessment
8.6 Revenue Forecast by Major Asset
8.7 Competitive Launch Overlap Analysis
8.8 Commercial Adoption Outlook
8.9 Long-Term Market Evolution

9. Competitive Pipeline Landscape

9.1 Competitive Environment Overview
9.2 Company-Wise Pipeline Strength Assessment
9.3 Leading Sponsors by Pipeline Size
9.4 Leading Sponsors by Clinical Stage
9.5 Innovation Leadership Analysis
9.6 Pipeline Concentration Assessment
9.7 Leader versus Challenger Positioning
9.8 Competitive Benchmarking Matrix
9.9 Emerging Entrants Analysis
9.10 Strategic Positioning Assessment

10. Geographic Analysis (Regional Level Only)

10.1 North America
- 10.1.1 Clinical Trial Activity
- 10.1.2 Regulatory Environment
- 10.1.3 Innovation Ecosystem
10.2 Europe
- 10.2.1 Clinical Trial Activity
- 10.2.2 Regulatory Environment
- 10.2.3 Innovation Ecosystem
10.3 Asia-Pacific
- 10.3.1 Clinical Trial Activity
- 10.3.2 Regulatory Environment
- 10.3.3 Innovation Ecosystem
10.4 Latin America
- 10.4.1 Clinical Trial Activity
- 10.4.2 Regulatory Environment
- 10.4.3 Innovation Ecosystem
10.5 Middle East & Africa
- 10.5.1 Clinical Trial Activity
- 10.5.2 Regulatory Environment
- 10.5.3 Innovation Ecosystem

11. Key Countries Analysis

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 China
11.9 Japan
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Deals & Investment Landscape

12.1 Licensing Agreements
12.2 Co-Development Collaborations
12.3 Research Partnerships
12.4 Mergers and Acquisitions
12.5 Venture Capital Investments
12.6 Private Equity Investments
12.7 Public Funding Initiatives
12.8 Strategic Alliance Trends
12.9 Investment Hotspots
12.10 Future Funding Outlook

13. Future Outlook & Strategic Insights

13.1 Genentech
- 13.1.1 Pipeline Positioning
- 13.1.2 Strategic Priorities
- 13.1.3 Future Outlook
13.2 Boehringer Ingelheim
- 13.2.1 Pipeline Positioning
- 13.2.2 Strategic Priorities
- 13.2.3 Future Outlook
13.3 F. Hoffmann-La Roche Ltd
- 13.3.1 Pipeline Positioning
- 13.3.2 Strategic Priorities
- 13.3.3 Future Outlook
13.4 Novartis AG
- 13.4.1 Pipeline Positioning
- 13.4.2 Strategic Priorities
- 13.4.3 Future Outlook
13.5 Bayer AG
- 13.5.1 Pipeline Positioning
- 13.5.2 Strategic Priorities
- 13.5.3 Future Outlook
13.6 Johnson & Johnson
- 13.6.1 Pipeline Positioning
- 13.6.2 Strategic Priorities
- 13.6.3 Future Outlook
13.7 Daiichi Sankyo
- 13.7.1 Pipeline Positioning
- 13.7.2 Strategic Priorities
- 13.7.3 Future Outlook
13.8 Sanofi
- 13.8.1 Pipeline Positioning
- 13.8.2 Strategic Priorities
- 13.8.3 Future Outlook
13.9 Novo Nordisk
- 13.9.1 Pipeline Positioning
- 13.9.2 Strategic Priorities
- 13.9.3 Future Outlook
13.10 AstraZeneca PLC
- 13.10.1 Pipeline Positioning
- 13.10.2 Strategic Priorities
- 13.10.3 Future Outlook
13.11 Merck & Co., Inc.
- 13.11.1 Pipeline Positioning
- 13.11.2 Strategic Priorities
- 13.11.3 Future Outlook
13.12 GlaxoSmithKline plc
- 13.12.1 Pipeline Positioning
- 13.12.2 Strategic Priorities
- 13.12.3 Future Outlook
13.13 Eli Lilly and Company
- 13.13.1 Pipeline Positioning
- 13.13.2 Strategic Priorities
- 13.13.3 Future Outlook
13.14 AbbVie Inc.
- 13.14.1 Pipeline Positioning
- 13.14.2 Strategic Priorities
- 13.14.3 Future Outlook
13.15 Future Pipeline Evolution Scenarios
13.16 Emerging Technology Assessment
13.17 Strategic Recommendations
13.18 Key Success Factors Through 2035